Le Lézard
Classified in: Health
Subject: SVY

Europe Osteopenia Market Forecasts 2018-2026


DUBLIN, July 13, 2018 /PRNewswire/ --

The "Europe Osteopenia Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The research provides insights into Osteopenia epidemiology, Osteopenia diagnosed patients, and Osteopenia treatment rate for EU5 countries. The research measures key indicators including prevalence of Osteopenia derived from epidemiological analysis, patients diagnosed with Osteopenia, and patients treated with a drug therapy.

The research study helps executives estimate Osteopenia market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The research provides estimates and forecasts of Osteopenia prevalence, Osteopenia diagnosis rate, and Osteopenia treatment rate for the period 2017-2026. The information is presented by EU5 countries including Germany, France, Spain, Italy, and UK.


Key Topics Covered




1. Osteopenia: Disease Definition



2. Osteopenia Patient Flow in Europe


2A. Osteopenia Prevalence in Europe


2B. Osteopenia Diagnosed Patients in Europe


2C. Osteopenia Treated Patients in Europe



3. Osteopenia Patient Flow in Germany


3A. Osteopenia Prevalence in Germany


3B. Osteopenia Diagnosed Patients in Germany


3C. Osteopenia Treated Patients in Germany



4. Osteopenia Patient Flow in France


4A. Osteopenia Prevalence in France


4B. Osteopenia Diagnosed Patients in France


4C. Osteopenia Treated Patients in France



5. Osteopenia Patient Flow in Spain


5A. Osteopenia Prevalence in Spain


5B. Osteopenia Diagnosed Patients in Spain


5C. Osteopenia Treated Patients in Spain



6. Osteopenia Patient Flow in Italy


6A. Osteopenia Prevalence in Italy


6B. Osteopenia Diagnosed Patients in Italy


6C. Osteopenia Treated Patients in Italy



7. Osteopenia Patient Flow in UK


7A. Osteopenia Prevalence in UK


7B. Osteopenia Diagnosed Patients in UK


7C. Osteopenia Treated Patients in UK



8. Research Methodology



For more information about this report visit

https://www.researchandmarkets.com/research/xv77ds/europe_osteopenia?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 



SOURCE Research and Markets


These press releases may also interest you

at 01:30
The shares in Aker ASA will be traded ex-dividend NOK 15.50 as from today, 18 April 2024. Investor contact:Fredrik Berge, Head of Investor Relations Aker ASA Tel: +47 450 32 090 E-mail: [email protected] Media contact:Atle Kigen, Head of...

at 00:00
Health Carousel, renowned for its dedication to enhancing the healthcare staffing sector, today unveiled its groundbreaking 'Full Circle of Support' program. This initiative represents a significant investment in the total well-being of its...

17 avr 2024
TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to...

17 avr 2024
SysInformation Healthcare Services, LLC ("SysInformation"), d/b/a EqualizeRCM and 1st Credentialing, is providing notice of a recent data security event that may affect the security of information related to certain individuals. SysInformation is...

17 avr 2024
Scottie Resources Corp. ("Scottie" or the "Company") announces that it has granted 7,400,000 options to acquire common shares to certain directors, officers, and consultants to the Company. The options are exercisable at a price of $0.195 per...

17 avr 2024
DaVita Inc. , announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, May 2, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is...



News published on and distributed by: